MDxHealth: UnitedHealth to provide commercial coverage for GPs test

MDxHealth (MDXH) announced that UnitedHealthcare (UNH) will cover the mdxhealth Genomic Prostate Score GPS test ( under UnitedHealthcare’s commercial policies to assist with treatment decisions for individuals newly diagnosed with localized prostate cancer and meeting coverage criteria.Michael K. McGarrity, CEO of mdxhealth, commented: "We are very pleased to announce that UnitedHealthcare, the largest private health insurer in the United States, will provide coverage for our Genomic Prostate Score test. We applaud UnitedHealthcare’s decision to identify our GPS test as its only commercially-covered diagnostic that can improve clinical outcomes for men newly diagnosed with localized prostate cancer."In its technical assessment of commercially available genomic panels for stratifying risk in individuals with prostate cancer, UnitedHealthcare’s updated Medical Policy cites findings that "the body of evidence consistently favors use of the GPS assay to assist with management strategies…" UnitedHealthcare’s commercial coverage of GPS supplements coverage that GPS has from other national and regional commercial payers, as well as from Medicare and Medicare Advantage plans.